Parvovirus B19 Status in Liver, Kidney and Pancreas Transplant Candidates: A Single Center Experience

Overview

Journal World J Transplant

Publisher Baishideng Publishing Group

Specialty General Surgery

Date 2022 Nov 28

PMID 36437842

Authors

Bojana Simunov

Anna Mrzljak

Zeljka Jurekovic

Snjezana Zidovec Lepej

Ana Bainrauch

Jadranka Pavicic Saric

Zeljka Hruskar

Leona Radmanic

Tatjana Vilibic-cavlek

Affiliations

Soon will be listed here.

Abstract

Background: Parvovirus B19 (B19V) is associated with a wide range of clinical manifestations. The major presentation is erythema infectiosum. However, a persistent infection may cause pure red cell aplasia and chronic anemia in immunocompromized patients. The B19V seroprevalence varies with age and geographical location.

Aim: To determine the B19V serological status and DNAemia in kidney, liver, and pancreas transplant candidates.

Methods: Patients who underwent kidney, liver, or simultaneous kidney and pancreas/liver transplantation between January 2021 and May 2022 were included in the study. The serum samples were collected before transplantation. For detection of B19V DNA, a LightMix Kit B19V EC (TIB MOLBIOL, Berlin, Germany) was used. B19V IgM and IgG antibodies were detected using a commercial ELISA test (Euroimmun, Lübeck, Germany).

Results: One hundred and thirty-one transplant candidates were included in the study, 71.0% male, with an average age of 53.27 years ± 12.71 years. There were 68.7% liver, 27.5% kidney, 3.0% simul taneous pancreas/kidney transplant (SPKT), and 0.8% simultaneous liver/kidney transplant recipients. No patients had detectable B19V DNA. B19V IgG seroprevalence was 77.1%. No acute or recent infections were detected (IgM antibodies). There was no difference in the mean age of seronegative and seropositive patients (51.8 years ± 12.9 years 53.7 years ± 12.7 years, = -0.603; = 0.548). Although seropositivity was lower in patients aged less than 30 years (66.6%) compared to the patients aged 30-59 years and > 60 years (80.4% and 78.1%, respectively), this difference was not significant. In addition, there was no difference in seropositivity between male and female transplant candidates, 76.3% and 78.9% ( = 0.104; = 0.748). The seroprevalence did not differ among organ recipients, with 77.8%, 80.6%, and 50.0% for liver, kidney, and SPKT, respectively, ( = 5.297; = 0.151). No significant difference was found in the seroprevalence in kidney transplant patients according to dialysis modality. Seroprevalence was 71.1% in hemodialysis patients, and 100% in peritoneal dialysis patients ( = 0.799; = 0.372).

Conclusion: The B19V seroprevalence is expectedly high among kidney, liver, and pancreas transplant candidates, but there are still 22.9% of seronegative individuals who remain at risk for primary disease and severe manifestations. Further research should elucidate the necessity of B19V screening in peri-transplant management.

References

Anderson M, Higgins P, Davis L, Willman J, Jones S, Kidd I . Experimental parvoviral infection in humans. J Infect Dis. 1985; 152(2):257-65. DOI: 10.1093/infdis/152.2.257. View

Lindahl J, Barlinn R, Abrahamsen I, Spetalen S, Midtvedt K, Jenssen T . Case Report: Pure Red Cell Aplasia Caused by Refractory Parvovirus B19 Infection After Pancreas Transplantation Alone. Front Med (Lausanne). 2022; 9:849783. PMC: 8966125. DOI: 10.3389/fmed.2022.849783. View

Huang Q, Wang Y, Chen R, Zhao Y, Wang H, Ma X . Parvovirus B19 infection in kidney transplant recipients: A prospective study in a teaching hospital in Shanghai, China. Transpl Immunol. 2022; 74:101667. DOI: 10.1016/j.trim.2022.101667. View

Wang H, Fu Y, Song W, Wang Z, Feng G, Zhao J . Human parvovirus B19-associated early postoperative acquired pure red cell aplasia in simultaneous pancreas-kidney transplantation: A case report. World J Clin Cases. 2021; 9(8):1968-1975. PMC: 7953402. DOI: 10.12998/wjcc.v9.i8.1968. View

Pamidi S, Friedman K, Kampalath B, Eshoa C, Hariharan S . Human parvovirus B19 infection presenting as persistent anemia in renal transplant recipients. Transplantation. 2000; 69(12):2666-9. DOI: 10.1097/00007890-200006270-00030. View

Barzon L, Murer L, Pacenti M, Biasolo M, Della Vella M, Ghirardo G . Detection of viral DNA in kidney graft preservation and washing solutions is predictive of posttransplant infections in pediatric recipients. J Infect Dis. 2009; 200(9):1425-33. DOI: 10.1086/644504. View

Servey J, Reamy B, Hodge J . Clinical presentations of parvovirus B19 infection. Am Fam Physician. 2007; 75(3):373-6. View

Prasad B, St Onge J . Parvovirus leading to thrombotic microangiopathy in a healthy adult. BMJ Case Rep. 2016; 2016. PMC: 4735274. DOI: 10.1136/bcr-2015-213492. View

Renoult E, Bachelet C, Krier-Coudert M, Diarrassouba A, Andre J, Kessler M . Recurrent anemia in kidney transplant recipients with parvovirus B19 infection. Transplant Proc. 2006; 38(7):2321-3. DOI: 10.1016/j.transproceed.2006.06.116. View

10.

Mage V, Lipsker D, Barbarot S, Bessis D, Chosidow O, Del Giudice P . Different patterns of skin manifestations associated with parvovirus B19 primary infection in adults. J Am Acad Dermatol. 2014; 71(1):62-9. DOI: 10.1016/j.jaad.2014.02.044. View

11.

Zhong Q, Zeng J, Lin T, Song T . The detection, treatment of parvovirus B19 infection induced anemia in solid organ transplants: A case series and literature review of 194 patients. Transfus Clin Biol. 2022; 29(2):168-174. DOI: 10.1016/j.tracli.2021.12.005. View

12.

Steffen C, Koch N, Eckardt K, Amann K, Seelow E, Schreiber A . Hemophagocytic lymphohistiocytosis and thrombotic microangiopathy after parvovirus B19 infection and renal transplantation: a case report. BMC Nephrol. 2021; 22(1):337. PMC: 8506469. DOI: 10.1186/s12882-021-02538-0. View

13.

Bultmann B, Klingel K, Sotlar K, Bock C, Kandolf R . Parvovirus B19: a pathogen responsible for more than hematologic disorders. Virchows Arch. 2003; 442(1):8-17. DOI: 10.1007/s00428-002-0732-8. View

14.

Rezahosseini O, Ekenberg C, Moller D, Schwartz Sorensen S, Wareham N, Perch M . Incidence and Impact of Parvovirus B19 Infection in Seronegative Solid Organ Transplant Recipients. J Infect Dis. 2021; 224(5):865-869. DOI: 10.1093/infdis/jiab024. View

15.

Bayer G, Von Tokarski F, Thoreau B, Bauvois A, Barbet C, Cloarec S . Etiology and Outcomes of Thrombotic Microangiopathies. Clin J Am Soc Nephrol. 2019; 14(4):557-566. PMC: 6450353. DOI: 10.2215/CJN.11470918. View

16.

Ki C, Kim I, Kim J, Lee N, Kim S, Lee K . Incidence and clinical significance of human parvovirus B19 infection in kidney transplant recipients. Clin Transplant. 2005; 19(6):751-5. DOI: 10.1111/j.1399-0012.2005.00415.x. View

17.

Cossart Y, Field A, Cant B, Widdows D . Parvovirus-like particles in human sera. Lancet. 1975; 1(7898):72-3. DOI: 10.1016/s0140-6736(75)91074-0. View

18.

Krygier D, Steinbrecher U, Petric M, Erb S, Chung S, Scudamore C . Parvovirus B19 induced hepatic failure in an adult requiring liver transplantation. World J Gastroenterol. 2009; 15(32):4067-9. PMC: 2731960. DOI: 10.3748/wjg.15.4067. View

19.

Gosset C, Viglietti D, Hue K, Antoine C, Glotz D, Pillebout E . How many times can parvovirus B19-related anemia recur in solid organ transplant recipients?. Transpl Infect Dis. 2012; 14(5):E64-70. DOI: 10.1111/j.1399-3062.2012.00773.x. View

20.

Carraturo A, Catalani V, Ottaviani D, Menichelli P, Rossini M, Terella D . Parvovirus B19 infection and severe anemia in renal transplant recipients. ScientificWorldJournal. 2012; 2012:102829. PMC: 3349305. DOI: 10.1100/2012/102829. View